FDA Grants AP Status for Bosentan ANDA207110 by Watson Labs
The FDA has granted approval status (AP) for Watson Labs' ANDA207110 for Bosentan.
Published: July 26, 2026
Updated: July 26, 2026
Author: Humanexa Intelligence
Therapeutic area: Cardiology / Endothelin Receptor Antagonist
Company: Watson Labs
Asset: Bosentan
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Watson Labs
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's grant of approval status for Watson Labs' ANDA207110 for Bosentan is significant as it opens the door for increased competition in the cardiology market. Portfolio teams must evaluate the implications for market share and pricing strategies as Watson Labs prepares to enter the market.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the final approval and market launch timeline for ANDA207110.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.